Search

Your search keyword '"Bajracharya R."' showing total 187 results

Search Constraints

Start Over You searched for: Author "Bajracharya R." Remove constraint Author: "Bajracharya R."
187 results on '"Bajracharya R."'

Search Results

1. Organometallic Phyllosilicate-Gold Nanocomplex: An Effective Oral Delivery System of Methotrexate for Enhanced in vivo Efficacy Against Colorectal Cancer

2. Lifestyle changes in middle age and risk of cancer: evidence from the European Prospective Investigation into Cancer and Nutrition

3. AB0881 LONG-TERM SAFETY AND TOLERABILITY OF BIMEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM POOLED PHASE 2B/3 STUDIES

4. Advancements in the Pharmaceutical Applications of Probiotics: Dosage Forms and Formulation Technology

6. PCR229 Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year

7. Tolérance à long terme du bimékizumab chez les patients atteints de spondyloarthrite axiale (axSpA) et de rhumatisme psoriasique (RhPso) : résultats groupés des études de phase IIb/III

8. Maintien de l’efficacité du bimékizumab pendant 52 semaines chez les patients atteints de rhumatisme psoriasique, naïfs de biologique et répondeurs à la semaine 16 : résultats de BE OPTIMAL, étude de phase III avec un bras de référence actif

9. Impact du bimékizumab sur les domaines évalués par le GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) chez les patients atteints de rhumatisme psoriasique (RhPso) : résultats à 52 semaines issus de 4 études de phase III

11. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

12. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study

13. AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR

14. POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR

15. POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL

16. AB1100 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL DISEASE CONTROL CRITERIA WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION, PAIN AND FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM BE OPTIMAL, A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDY

18. PCR117 Achieving Stringent Clinical Disease Control Criteria Is Associated With Improved Quality of Life Measures in Patients With Active Psoriatic Arthritis: Results From Two Phase 3 Randomised, Placebo-Controlled Studies

19. Le bimékizumab réduit fatigue et douleur chez les patients atteints de rhumatisme psoriasique actif, naïfs de biologiques ou avec réponse inadéquate (RI) aux anti-TNF : résultats à 16 semaines de 2 études de phase III randomisées, contrôlées par placebo

20. L’atteinte de critères cliniques plus stricts est associée à de plus importantes améliorations des critères patients (fonction physique, douleur) chez les patients atteints de rhumatisme psoriasique actif : résultats à 16 semaines de 2 études de phase III

21. Le bimékizumab améliore la qualité de vie chez les patients atteints de rhumatisme psoriasique actif, naïfs de biologiques ou avec réponse inadéquate aux anti-TNF : résultats à 16 semaines de 2 études de phase III randomisées, contrôlées par placebo

22. Le bimékizumab chez des patients atteints de rhumatisme psoriasique et naïfs de biologique : évaluation de l’efficacité et de la tolérance à 24 semaines dans une étude de phase III

23. Le bimékizumab chez des patients atteints de rhumatisme psoriasique et présentant une réponse inadéquate aux anti-TNF : évaluation de l’efficacité et de la tolérance à 16 semaines dans une étude de phase III

24. Ultrasound-mediated delivery of novel tau-specific monoclonal antibody enhances brain uptake but not therapeutic efficacy

25. OP0255 BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY

26. LB0001 BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY

28. Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain

36. ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL DISEASE CONTROL CRITERIA WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION, PAIN AND FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM BE OPTIMAL, A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDY

37. SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR

39. SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR.

40. Erosion Effects on Carbon Dioxide Concentration and Carbon Flux from an Ohio Alfisol

41. Diurnal and Seasonal [CO.sup.2]-C Flux from Soil as Related to Erosion Phases in Central Ohio

42. Assessing bioenergetic functions from isolated mitochondria in the fly Drosophila melanogaster

43. SUSTAINABLE DIVERSIFIED AGRICULTURE AND LAND MANAGEMENT IN THE HIMALAYA: IMPLICATIONS FOR CLIMATE CHANGE ADAPTATION AND MITIGATION

Catalog

Books, media, physical & digital resources